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Nontuberculous mycobacteria in 
Denmark, incidence and clinical 
importance during the last quarter-
century
Thomas S. Hermansen1,2, Pernille Ravn2, Erik Svensson  1 & Troels Lillebaek1
Disease caused by nontuberculous mycobacteria (NTM) is reported to increase due to an ageing 
population and a rise in the proportion of immunosuppressed patients. We did a retrospective cohort 
study of NTM-disease in the Danish population through a quarter-century to determine the disease 
burden and trends in annual incidence rates. 524,119 clinical specimens were cultured for mycobacteria 
from 1991 through 2015 at the International Reference Laboratory of Mycobacteriology in Denmark. 
Among these, 8,227 NTM strains were identified from 3,462 patients and distributed according to 
microbiological disease criteria. We observed no increase in NTM disease incidence or proportion of 
patients with positive NTM cultures during the study period (Quasi-Poisson regression, p = 0.275 
and 0.352 respectively). Annual incidence rates were 1.20/105 for definite NTM disease, 0.49/105 for 
possible NTM disease and 0.88/105 for NTM colonization. The incidence rate of NTM disease was 
highest in children aged 0-4 years (5.36/105/year), predominantly with cervical Mycobacterium avium 
complex (MAC) adenitis. Surprisingly, based on more than half a million clinical specimens cultured 
for mycobacteria in Denmark through 25 years, the NTM disease burden and trend in incidence in the 
Danish population has not increased opposed to numerous internationals reports.
Non-tuberculous mycobacteria (NTM) are ubiquitous in the environment worldwide1, 2. It’s a heterogeneous 
group of opportunistic pathogens causing human disease predominantly in immuno-compromised individuals 
and patients with underlying disease such as bronchiectasis and cystic fibrosis3. Clinical disease caused by NTM 
can be very diverse and present with pulmonary lesions and involve extra-pulmonary sites such as lymph nodes, 
skin and soft tissue, bones and joints. NTM disease can also mimic infection caused by Mycobacterium tuber-
culosis. Both pulmonary NTM colonization and NTM disease have a five-year mortality of approximately 40%, 
reflecting the high level of comorbidity and/or immune suppression in these patients4.
Several studies have reported an increase in both NTM disease and NTM colonization in humans during the 
last decades5–10. The increase in NTM disease has been attributed to different factors such as improved culturing 
techniques and greater disease awareness, but it has also been attributed to a true increase in disease incidence as 
a result of increased life expectancy and an increasing proportion of the population experiencing immunosup-
pression due to medication or suffering from immune-modulating comorbidities such as e.g. diabetes mellitus 
and chronic obstructive pulmonary disease (COPD)11–13.
The majority of studies assessing the significance of NTM colonization and disease have some important lim-
itations. First, the true clinical impact of NTM infections is difficult to assess due to challenges in discriminating 
between disease and colonization13. Second, in most countries, NTM diseases are not notifiable, thus population 
data are not routinely collected, and incidence rates are based mainly on the numbers of NTM isolated. Finally, 
the majority of studies have been conducted in localized geographic regions within countries, sometimes based 
on few observations and/or short observation period, limiting the overall generalizability of results5, 8, 10, 14, 15.
In Denmark, for almost one century, the culturing of mycobacteria has been centralized to one laboratory 
only, the International Reference Laboratory of Mycobacteriology (IRLM) in Copenhagen. This, allows a very 
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comprehensive and exhaustive evaluation of NTM disease burden and trends in annual incidence rates during 
decades based on microbiological criteria.
Material and Methods
Data sources and study design. Retrospective nationwide cohort study including data from IRLM, 
Denmark, on all patients with a positive NTM culture from January 1991 through December 2015. IRLM is the 
only laboratory in Denmark which routinely cultivates mycobacteria. The first positive NTM culture per patient 
was used for incidence rate calculations, whereas the total number of cultures per patient was used for allocating 
patients into disease categories. If a patient was culture-positive for more than one NTM species during the study 
period, only the first NTM was included in the study (n = 41, 1.2% of the patients).
Description of variables. Patients were classified into three NTM disease categories using the modified 
American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) 2007 criteria based on microbi-
ological data only13: definite NTM disease, possible NTM disease, and NTM colonization. This method has been 
validated by Andrejak et al. in 20104. In addition to the modified ATS/IDSA criteria focusing on pulmonary cases, 
we included patients with NTM cultured from extra-pulmonary sites as definite NTM disease cases in line with 
Freeman et al.16.
Patients were considered to have “definite NTM disease” if they had; A) more than three positive specimens, 
B) three positive specimens including one or more positive specimen obtained by bronchoscopy, C) three positive 
specimens including one or more positive bronchial wash, bronchial biopsy or pleural effusion, D) at least one 
positive specimen from a lung biopsy, or E) a positive specimen from an extra-pulmonary location. Patients were 
considered to have “NTM colonization”, if they had only one positive NTM specimen, unless this specimen was 
from; a bronchial wash, a lung or bronchial biopsy, or an extra-pulmonary location. The remaining patients were 
categorized as “possible NTM disease” based on their fulfilment of microbiological ATS/IDSA criteria of NTM 
disease without any available clinical data, expect for patients with only one positive culture for M. gordonae from 
a bronchial wash, whom were classified as NTM colonization.
Gastric lavage aspirations were excluded from our study because they were considered a result of contamina-
tion. The majority of cultures (78%) contained M. gordonae and were from 1998 and 1999, where tap water was 
used for gastric aspirations resulting in a surge in cultures without clinical relevance.
The patients were divided into three groups; a) Patients with respiratory samples were classified as pulmonary 
NTM, b) patients with samples from non-respiratory sites (including pleura) were classified as non-pulmonary 
NTM, and c) patients with samples from both pulmonary and non-pulmonary sites were classified as multifocal 
NTM.
Patient age was calculated from the unique Personal Identification Number in the Danish Civil Registration 
System17. The incidence rates were stratified in five-year age intervals standardized to the population demo-
graphics18. This standardization ensured that disease events were not disproportionately weighted in extreme age 
groups. Annual incidence rates were calculated based on an increase in the Danish population from 5,148,000 in 
1991 to 5,658,000 in 2015.
NTM species identification was carried out by either AccuProbe (Gen-Probe, San Diego, CA) and supplemen-
tary biochemical tests (1991–2001), InnoLipa species (InnoGenetics, Ghent, Belgium, 2001–2012) or GenoType 
Mycobacterium CM/AS (Hain Lifescience, 2012–2015). Throughout the study period, 16 S DNA sequencing 
using primers directed at the hypervariable region A was used as a supplement when species were not identifiable 
by other methods19. The most common NTM species encountered were included individually in the analysis, the 
remaining species were referred to as “Others”.
Statistics. The quantitative variables were described as mean and standard deviation of normally distributed 
variables and as median and interquartile range of non-normally distributed variables. The qualitative variables 
were described as numbers and percentages out of the total.
Incidence rates were found by summarising the mid-year population estimates for the Danish population 
each year during the study period. To evaluate a trend in annual incidence rates of NTM disease during the study 
period, we constructed a Quasi-Poisson regression model. This was chosen to allow for over-dispersion of data. 
We corrected for serial correlation by adding the observed incidence rate the previous year as explanatory variable 
in the model. Relative risks (RR) with 95% confidence intervals (CI) for definite or possible NTM disease in the 
different age groups were calculated. Multiple group comparisons were performed using the non-parametrically 
Kruskal-Wallis rank sum test to investigate the association between patient age and year of NTM culture accord-
ing to gender. The χ2 test for trend in proportions was used to evaluate the association between year of culture 
and the proportions of NTM colonization versus NTM definite and possible disease. A non-significant trend test 
indicates no linear trend towards an increase or decrease during the study period. A significance level of p < 0.05 
was considered significant. For the statistical analysis, R version 3.1.1 was used.
Ethics. The study was approved by the Danish Data Protection Agency J.no.: 2012-54-0100. Permission from 
an ethical committee was not required.
Results
From 1991 through 2015, IRLM performed 524,119 cultures. Among these, 8227 (1.6%) were NTM culture pos-
itive, retrieved from 3,462 individuals. Using microbiological criteria; 1,618 (47%) patients had definite NTM 
disease, 654 (19%) had possible NTM disease and 1,190 (34%) NTM colonization. 2,391 (69.1%) of samples were 
from pulmonary sites, 926 (26.7%) from non-pulmonary sites, and 145 (4.2%) from multifocal sites. In total, 51 
different species were isolated. For frequency of NTM species according to disease category, age, localization 
of disease, and sex, see Table 1. Annual numbers and proportions of patients in the three disease categories are 
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shown in Table 2. The annual number of positive cultures in the population did not increase or decrease during 
the study period (p = 0.836, data not shown).
NTM incidence rates. During the study period, we found no significant trend when calculating the over-
all incidence rate for patients with a positive NTM culture (definite NTM disease, possible NTM disease and 
NTM colonization combined, p = 0.3516, Fig. 1). The overall annual incidence rate was 2.57/105; 1.20/105 for 
definite NTM disease, 0.49/105 for possible NTM disease, and 0.88/105 for NTM colonization. Also, we found 
no significant trend for definite NTM disease (p = 0.674) (Fig. 1) or for the combined incidence rates of definite 
NTM disease and possible NTM disease (p = 0.275) (Fig. 1). Similarly, the incidence rate for patients with NTM 
colonization did not increase or decrease during the study period (p = 0.663).
NTM and age. Age-standardized incidence rates revealed significant differences according to age groups 
(Table 3 and Fig. 2). Among the adult population aged 15 years and above, the incidence of definite NTM dis-
ease, possible NTM disease, and NTM colonization were 0.99/105/year, 0.59/105/year and 1.06/105/year, respec-
tively. Thus, a large proportion of NTM cultures represented possible disease (647/2,901; 22%) and colonization 
(1,167/2,901; 40%). Reversely, among children, the majority of positive NTM cultures represented definite disease 
(530/561; 95%) (Fig. 2). The 0–4 years group had an incidence rate of NTM disease of 5.36/105/year and the 
relative risk (RR) of a positive NTM culture among children aged 0–4 years was 10.0 (95% CI [7.3-13.8]) com-
pared to the reference age group with the lowest annual incidence; adolescents aged 15–19 years. Among adults, 
age-adjusted incidence rates were at a steady level among the age groups 15–54 years (0.54–1.92/105), increasing 
from age 55 years. The median age of all adults (15 + years) increased during the study period from 49.4 (IQR 
34.1) in 1991 to 68.2 (IQR 19.2) in 2015 (p < 0.00001, Kruskal-Wallis) (data not shown in table).
NTM species. The five most commonly identified species in the Danish population were MAC (n = 1,757), 
M. gordonae (n = 527), M. abscessus/chelonae (n = 195), M. malmoense (N = 139), and M. xenopi (n = 140) 
(Table 1). There was no difference in male to female ratio compared to the overall distribution, except for M. 
marinum (72% males). MAC accounted for 51% (1,757/3,462) of all NTM isolates and 68% (1,093/1,618) of all 
definite NTM disease cases, as the most commonly identified species. MAC was responsible for 80% (448/561) 
of all isolates in children aged 0–14 years, and 98% of these children had definite disease (Table 1). The annual 
incidence rate of definite NTM disease with MAC among children aged 0–4 was 4.6/105. A complete list of all 
species in the study period is available in Table 4.
Localization of NTM disease. The overall incidence of pulmonary- and non-pulmonary NTM cultures 
were 1.78/105/year and 0.69/105/year, respectively. However, adults and children differed. Adults aged 15 and 
above had an annual incidence rate from a pulmonary or non-pulmonary site of 2.14/105 and 0.38/105, respec-
tively. Conversely, children had an annual incidence of non-pulmonary NTM cultures of 2.00/105/year, whereas 
the incidence of NTM cultures from a pulmonary site was 0.20/105/year. The relation between young age and 
extra-pulmonary NTM site was related to MAC infections; 95% of all clinical specimens containing MAC in 
children originated from lymph nodes. Conversely, among persons aged > 14 years, MAC was isolated from 
pulmonary sites for 75% of cases and from non-pulmonary sites for only 16% of cases (Table 1), whereas 9% were 
from multifocal sites. Localization of NTM disease also differed according to species. M. marinum was isolated 
from an extra-pulmonary site in 98% of the cases, while 1% was pulmonary and 1% multifocal. Conversely, M. 
xenopi was isolated from a pulmonary site in 95% of cases.
NTM species
Total
Definite NTM 
disease
Possible NTM 
disease
NTM coloni-
zation Age Median 
[IQR]
Localisation 
Pulmonary %
Localisation Non 
pulmonary %
Sex 
male%n n n n
M. abscessus/chelonae 195 93 37 65 46.6 [45.2] 82.6 15.9 54.4
M. avium complex 1,757 1,093 403 261 55.0 [59.1] 56.9 35.9 52.6
  Adults aged 15+* 1,309 652 400 257 64.2 [26.0] 75.1 15.5 56.3
  Children aged 0–14† 448 441 3 4 2.5 [2.0] 3.8 95.3 41.7
M. gordonae 527 0 0 527 65.9 [21.9] 94.1 5.5‡ 58.4
M. kansasii 55 34 15 6 50.0 [36.4] 83.6 12.7 58.2
M. malmoense 139 97 23 19 59.5 [42.0] 71.2 28.8 55.4
M. marinum 100 100 0 0 44.4 [27.4] 1.0 98.0 72.0
M. fortuitum/peregrinum 123 15 24 84 59.4 [31.0] 91.9 8.1 59.3
M. xenopi 140 61 42 37 63.6 [21.6] 95.0 2.9 60.0
Others§ 426 125 110 191 62.1 [25.5] 81.0 17.5 55.8
Total 3,462 1,618 654 1,190 58.5 [37.2] 69.1** 26.7** 55.4
Table 1. NTM frequency according to disease category, age, sample localization, and sex. *Among adults with 
MAC, 9.4% (123) were from a multifocal origin (total 1,309). †Among children 0.9% (4) were from a multifocal 
origin (a total of 448/561 samples were MAC). ‡Of these, 76% (22/29) of specimens were from urine or fecal 
samples. §Others including uncommon mycobacteria and mycobacteria not identified (a complete list is 
available in Table 4). **4.2% of samples were from a multifocal origin.
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Discussion
This is the largest nationwide study estimating the burden of NTM disease in a TB low incidence country to our 
knowledge. The study includes 524,119 mycobacterial cultures from all examined cases in Denmark through 
a quarter century. Based on this comprehensive and exhaustive dataset, we have evidence that contradicts the 
numerous reports of a general increase in NTM disease incidence5, 8, 10, 14, 15.
From 1991 through 2015, the annual incidence of culture-verified definite NTM disease and possible NTM 
disease remained steady. The overall incidence of positive cultures from pulmonary sites among adults was 
2.14/105/year; 1.10/105/year for cases with definite- and possible NTM disease. The incidence of cultures from 
non-pulmonary sites among adults (all definite NTM disease cases) was 0.38/105/year. These results are com-
parable to other studies in TB low incidence countries. In New Zealand, Freeman et al. found the pulmonary- 
and non-pulmonary NTM disease incidence to be 1.2/105/year and 0.63/105/year, respectively, while van Ingen 
reported an NTM disease incidence of 1.7/105 in the Netherlands in 200816, 20. In general, the incidence of NTM 
disease varies in different studies depending on study design, sample sites, diagnostic criteria, and geographical 
distribution, and different classifications of NTM disease versus NTM colonization is a challenge when compar-
ing studies9, 13, 21, 22. Furthermore, compared to our study covering a quarter-century, previous studies investigate 
1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003
Definite disease  
(%)
75  
(66)
60  
(69)
111  
(72)
80  
(56)
74  
(56)
81  
(56)
43  
(44)
36  
(22)
57  
(26)
49  
(40)
48  
(40)
47  
(56)
51  
(51)
Possible disease  
(%)
24  
(21)
21  
(24)
23  
(15)
22  
(15)
24  
(19)
24  
(17)
13  
(13)
18  
(11)
18  
(8)
10  
(8)
16  
(13)
16  
(19)
18  
(18)
Colonization  
(%)
15  
(13)
6  
(7)
21  
(14)
42  
(29)
30  
(23)
40  
(28)
41  
(42)
109  
(67)
143  
(66)
62  
(51)
55  
(46)
21  
(25)
30  
(30)
Total 114 87 155 144 128 145 97 163 218 121 119 84 99
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Definite disease  
(%)
50  
(45)
93  
(64)
49  
(47)
57  
(46)
63  
(45)
77  
(44)
72  
(42)
78  
(55)
85  
(52)
65  
(38)
53  
(36)
64  
(34)
Possible disease  
(%)
20  
(18)
20  
(14)
20  
(19)
23  
(18)
30  
(21)
23  
(13)
40  
(23)
37  
(26)
31  
(19)
35  
(21)
54  
(37)
75  
(39)
Colonization  
(%)
41  
(37)
32  
(22)
36  
(34)
45  
(36)
48  
(34)
75  
(43)
61  
(35)
27  
(19)
48  
(29)
70  
(41)
39  
(27)
52  
(27)
Total 111 145 105 125 141 175 173 142 164 170 146 191
Table 2. Annual number of NTM isolates in the study period. Percentages row wise each year (percentages 
differ 99–101 due to rounding).
Age, 
years
All NTM cultures Definite NTM disease Possible NTM disease NTM Colonization Localization*
n
Annual 
incidence /105 n
Annual 
incidence/105 n
Annual 
incidence/105 n
Annual 
incidence/105
%Pulmonary 
%Multifocal %Non-
pulmonary
0–4 429 5,40 424 5,34 2 0,03 3 0,04 2 1 97
5–9 83 0,93 73 0,82 4 0,04 6 0,07 13 1 85
10–14 47 0,56 33 0,40 1 0,01 13 0,16 71 2 27
15–19 42 0,54 25 0,32 4 0,05 13 0,17 72 2 26
20–24 51 0,62 26 0,32 7 0,09 18 0,22 63 8 28
25–29 96 1,05 43 0,47 21 0,23 32 0,35 46 19 35
30–34 137 1,39 75 0,76 24 0,24 38 0,39 45 17 38
35–39 138 1,40 62 0,63 25 0,25 51 0,52 51 15 34
40–44 151 1,60 73 0,77 25 0,27 53 0,56 58 11 31
45–49 178 1,92 75 0,81 30 0,32 73 0,79 64 11 25
50–54 182 1,83 72 0,72 32 0,32 78 0,78 77 6 17
55–59 257 3,13 104 1,27 54 0,66 99 1,20 87 2 11
60–64 286 4,42 118 1,83 65 1,01 103 1,59 89 1 10
65–69 377 6,83 132 2,39 94 1,70 151 2,73 92 2 5
70–74 365 6,95 100 1,90 91 1,73 174 3,31 94 1 5
75–79 311 6,60 102 2,16 80 1,70 129 2,74 94 1 5
80–84 222 6,87 53 1,64 67 2,07 102 3,16 94 1 6
85+ 110 4,30 28 1,09 28 1,09 54 2,11 92 0 8
Total 3,462 2.57 1,618 1.20 654 0.49 1,190 0.88 69 4 27
Table 3. Age standardized, annual incidence rates per 105 population and origin of NTM culture. NA: Not 
applicable. *Of all NTM cultures.
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NTM disease trends based on shorter time intervals up to maximal 12 years, thus the reported incidence- and 
prevalence rates are more susceptible to random fluctuations5, 8, 10, 14, 15.
In children, our evidence corroborates that the clinical manifestations of MAC are very different from adults. 
The most common clinical presentation of NTM disease in children is cervical adenitis most often due to myco-
bacteria from the M. avium complex (MAC)13. This localized lymph node enlargement is a chronic infection 
different from the pulmonary disease observed among adults, and it is occurring in immunocompetent chil-
dren aged 1–5 years without systemic symptoms13. In children < 15 years, 80% of all positive cultures were MAC 
infection, 95% of these from non-pulmonary sites. In contrast, among persons ≥ 15 years, MAC was identified 
in respiratory samples in 75% cases, 50% of these with definite NTM disease. The incidence of extra-pulmonary 
MAC disease in our study peaks in children aged 0–4 years, as seen in other studies23, 24. The high MAC incidence 
rates among children might reflect direct infection through the throat mucosa as children are more likely to have 
frequent direct contact with MAC sources in dirt, soil and water. Among adults, studies have shown that occupa-
tional exposure to soil is associated with an increased risk of MAC infections25. Also, a more immature cellular 
immunity in children could be part of the explanation; i.e. it has been suggested that T cell-dependant production 
of type 1 cytokines may be affected in children with lymphadenitis, and that the adenitis manifestation could be 
due to an impaired immunological response26, 27.
Figure 1. Annual incidence rates of definite NTM disease, possible NTM disease and NTM colonization. 
(a) Annual incidence rates of definite NTM disease, (b) annual incidence rates of definite and possible NTM 
disease and (c) annual incidence rates of total number of patients with a positive NTM culture. Quasi-Poisson 
generalized linear model found no trend towards an increase or decrease in the study period for definite NTM 
disease incidence (a, p = 0.674), definite and possible NTM disease incidence (b, p = 0.275) and patients with a 
positive NTM culture (c, p = 0.352).
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M. marinum originated from an extra-pulmonary site in the vast majority of cases (98%). Among these, the 
clinical specimen was a skin or wound biopsy in 90%, while the remaining sites were from a bone or joint biopsy. 
These findings confirm the presence of M. marinum as a pathogen prone to cause cutaneous infections28.
Elderly from age 65 had a relative risk of a positive NTM culture more than ten times that of adolescents aged 
15–19 when we calculated age-standardized incidence rates. This association between old age and an increased 
incidence of NTM disease is well known and has been associated with comorbidities in the ageing population29. 
In addition, we found the median age of patients with a positive NTM culture to increase during the last 25 
years. Initially, we hypothesized that increased longevity in the population was partly responsible for the expected 
Figure 2. Incidence rates of NTM disease categories in the study period standardized to age groups.
M. abscessus (131) M. interjectum (17)
M. agri (4) M. intracellulare (233)
M. arosiense (3) M. kansasii (55)
M. arupense (1) M. lentiflavum (8)
M. avium (1520) M. malmoense (139)
M. bohemicum (6) M. marinum (100)
M. branderi (5) M. mucogenicum (8)
M. brisbanense (1) M. neoaurum (2)
M. celatum (71) M. nonchromogenicum (5)
M. chelonae (64) M. novocastrense (2)
M. chimaera (4) M. palustre (3)
M. chitae (2) M. parascrofulaceum (3)
M. colombiense (3) M. peregrinum (19)
M. conceptionense (1) M. phocaicum (1)
M. cosmeticum (1) M. scrofulaceum (19)
M. europaeum (1) M. septicum (3)
M. flavescens (4) M. shimoidei (4)
M. fortuitum (104) M. simiae (18)
M. frederiksbergense (1) M. smegmatis (4)
M. gastri (2) M. szulgai (25)
M. genavense (11) M. terrae (5)
M. gilvum (2) M. triviale (1)
M. gordonae (527) M. vaccae (2)
M. haemophilum (1) M. ulcerans (2)
M. heckeshornense (4) M. xenopi (140)
M. heidelbergense (3)
Table 4. NTM species cultured from human specimens at IRLM 1991–2015, n = 51. (Uidentified mycobacteria 
n = 167).
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increase in NTM incidence rates found in other studies, but our study does not support this hypothesis, as our 
main finding is that the incidence of NTM disease did not increase during the study period.
Additionally, the incidence of patients with NTM colonization, did not increase during the study period. It 
could be that the clinical approach to diagnosing NTM disease has not changed during the study period, as an 
increased attention to NTM disease would intuitively result in more cultures and thus probably more cases of 
both NTM colonization and NTM disease. The steady annual number of specimens cultured at the IRLM during 
the study period supports this hypothesis, except for the years 1998 and 1999, where high rates of NTM coloniza-
tion were observed, the vast majority was due to M. gordonae (77% and 66% respectively), a known contaminant 
from tap water. This finding and subsequent decrease in clinical isolates containing M. gordonae is most likely due 
to an increased attention towards avoiding colonization replacing tap water with sterile water when performing 
diagnostic procedures.
Worldwide, the number of NTM disease cases surged in the eighties and nineties due to the HIV pandemic, 
when disseminated or extra-pulmonary Mycobacterial diseases often was seen as the AIDS-defining illnesses30. 
Later, after the introduction of highly active antiretroviral treatment (HAART) during 1996, there was a decline 
in AIDS-associated NTM disease31. To investigate HIVs potential influence on our results, we tried to exclude all 
NTM cases associated with AIDS by combining our data with the mandatory AIDS registry. Still, the incidence 
of definite NTM disease remained at a steady level during the study period (p = 0.854, see Table 5). Thus, the HIV 
pandemic did not influence our conclusions of no increase in NTM disease incidence.
Our study holds some limitations. First, the assignment of positive cultures to one of the three disease cate-
gories was solely based on microbiological criteria from the adapted ATS/IDSA guidelines for diagnosing NTM 
disease13. We had no access to information on treatment and the physicians’ diagnostic criteria. However, our 
approach has been used and validated several times and proven useful for epidemiological studies4, 12. Second, 
we report annual incidence rates of culture verified NTM disease. Thus, only patients suspected of mycobacterial 
disease are investigated, and only those with a positive NTM culture included. Therefore, the calculated incidence 
rates might underestimate the true NTM burden in the Danish population. However, we find it unlikely that 
(many) patients are treated for NTM disease without any positive culture(s) whatsoever. Therefore, we believe our 
finding of no trend towards an increase in NTM disease during the study period is valid.
In summary, based on more than half a million clinical specimens analysed for mycobacteria during a quarter 
century in Denmark, we cannot confirm the numerous reports on increasing incidence of NTM disease. Our 
finding highlights the need for a systematic approach to diagnosing NTM disease, including adherence to existing 
diagnostic guidelines. We need a uniform reporting of NTM disease and more studies critically questioning the 
NTM disease epidemiology.
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